Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2002 1
2005 1
2006 1
2009 1
2010 1
2011 2
2012 1
2013 3
2014 5
2015 5
2016 3
2017 1
2018 4
2019 1
2021 1
2022 3
2023 3
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Use of cardiac imaging in chronic coronary syndromes: the EURECA Imaging registry.
Neglia D, Liga R, Gimelli A, Podlesnikar T, Cvijić M, Pontone G, Miglioranza MH, Guaricci AI, Seitun S, Clemente A, Sumin A, Vitola J, Saraste A, Paunonen C, Sia CH, Paleev F, Sade LE, Zamorano JL, Maroz-Vadalazhskaya N, Anagnostopoulos C, Macedo F, Knuuti J, Edvardsen T, Cosyns B, Petersen SE, Magne J, Laroche C, Berlè C, Popescu BA, Delgado V; EURECA Investigators. Neglia D, et al. Eur Heart J. 2023 Jan 7;44(2):142-158. doi: 10.1093/eurheartj/ehac640. Eur Heart J. 2023. PMID: 36452988

In these patients, referral to stress imaging (21% vs. 58%; P < 0.001) or CTCA (17% vs. 30%; P < 0.001) was less frequent, while exercise ECG (43% vs. 22%; P < 0.001) and ICA (48% vs. 15%; P < 0.001) were more frequently performed. The adop

…

In these patients, referral to stress imaging (21% vs. 58%; P < 0.001) or CTCA (17% vs. 30%; P < 0.001) was less frequen

…
Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan.
Schoenen J, Pascual J, Rasmussen S, Sun W, Sikes C, Hettiarachchi J. Schoenen J, et al. Eur J Neurol. 2005 Feb;12(2):108-17. doi: 10.1111/j.1468-1331.2004.00893.x. Eur J Neurol. 2005. PMID: 15679698 Clinical Trial.
A slight majority (50.6%) preferred or greatly preferred eletriptan, whilst 43% preferred suma-sc. When permitted to choose between eletriptan and suma-sc for subsequent treatment, 78% of patients who had preferred eletriptan took eletriptan during the extension pha …
A slight majority (50.6%) preferred or greatly preferred eletriptan, whilst 43% preferred suma-sc. When permitted to choose between e …
Cardiac Magnetic Resonance to Predict Cardiac Mass Malignancy: The CMR Mass Score.
Paolisso P, Bergamaschi L, Angeli F, Belmonte M, Foà A, Canton L, Fedele D, Armillotta M, Sansonetti A, Bodega F, Amicone S, Suma N, Gallinoro E, Attinà D, Niro F, Rucci P, Gherbesi E, Carugo S, Musthaq S, Baggiano A, Pavon AG, Guglielmo M, Conte E, Andreini D, Pontone G, Lovato L, Pizzi C. Paolisso P, et al. Circ Cardiovasc Imaging. 2024 Mar;17(3):e016115. doi: 10.1161/CIRCIMAGING.123.016115. Epub 2024 Mar 19. Circ Cardiovasc Imaging. 2024. PMID: 38502734 Free PMC article.
The CMR mass score (range, 0-8 and cutoff, 5), including sessile appearance, polylobate shape, infiltration, pericardial effusion, first-pass contrast perfusion, and heterogeneity enhancement, showed excellent accuracy in predicting malignancy (areas under the curve, 0.976 [95% C …
The CMR mass score (range, 0-8 and cutoff, 5), including sessile appearance, polylobate shape, infiltration, pericardial effusion, first-pas …
Formulation, Configuration, and Physical Properties of Dental Composite Resin Containing a Novel 2π + 2π Photodimerized Crosslinker - Cinnamyl Methacrylate: An In Vitro Research.
Sreevarun M, Ajay R, Suganya G, Rakshagan V, Bhanuchander V, Suma K. Sreevarun M, et al. J Contemp Dent Pract. 2023 Jun 1;24(6):364-371. doi: 10.5005/jp-journals-10024-3480. J Contemp Dent Pract. 2023. PMID: 37534502
RESULTS: The configuration of the new copolymers P (BD-Co-CMA) and P(B-Co-CMA) was confirmed. The MPC% and T (g) of the copolymers were better than the control. PD-CMA at 20 wt. % in the P (B-Co-CMA) copolymer exhibited the highest MPC% and T(g) …
RESULTS: The configuration of the new copolymers P (BD-Co-CMA) and P(B-Co-CMA) was confirmed. The MPC% and T (g) of the …
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Nakarai C, Osawa K, Akiyama M, Matsubara N, Ikeuchi H, Yamano T, Hirota S, Tomita N, Usami M, Kido Y. Nakarai C, et al. Clin Exp Med. 2015 Aug;15(3):333-41. doi: 10.1007/s10238-014-0298-1. Epub 2014 Jun 17. Clin Exp Med. 2015. PMID: 24934327 Free PMC article.

The level of AKR1C3 mRNA expression was significantly different between the Dukes' stage A, B, and C groups and the control group (p < 0.05, p < 0.001, and p < 0.001) and was also significantly different between Dukes' stage C and A or B

…
The level of AKR1C3 mRNA expression was significantly different between the Dukes' stage A, B, and C groups and the control group ( …
Neuromyelitis optica: Clinical course and potential prognostic indicators.
Masha N, Kimbrough DJ, Eckstein CP, Hudak NM, Skeen MB, Hartsell FL, Lutz MW, Shah S. Masha N, et al. Mult Scler Relat Disord. 2023 Jan;69:104414. doi: 10.1016/j.msard.2022.104414. Epub 2022 Nov 19. Mult Scler Relat Disord. 2023. PMID: 36463620
Our results additionally revealed no significant association between clinical prognosis and initial AQP4 seropositivity (p = 0.830), initial AQP4 serum titer levels (p = 0.338), or administration of plasmapheresis (p = 0.1149). ...
Our results additionally revealed no significant association between clinical prognosis and initial AQP4 seropositivity (p = 0.830), …
Embodied transfer of knowledge using dynamic systems concepts in high school: A preliminary study.
Almarcha MC, Martínez P, Balagué N, Hristovski R. Almarcha MC, et al. Hum Mov Sci. 2022 Aug;84:102974. doi: 10.1016/j.humov.2022.102974. Epub 2022 Jul 6. Hum Mov Sci. 2022. PMID: 35809420
The Synthetic Understanding through Movement Analogies (SUMA) educational framework proposes embodied learning of general scientific principles and concepts and knowledge transfer among academic disciplines encompassing sciences, humanities and arts. ...Students followed f …
The Synthetic Understanding through Movement Analogies (SUMA) educational framework proposes embodied learning of general scientific …
Loss of FOCAD, operating via the SKI messenger RNA surveillance pathway, causes a pediatric syndrome with liver cirrhosis.
Moreno Traspas R, Teoh TS, Wong PM, Maier M, Chia CY, Lay K, Ali NA, Larson A, Al Mutairi F, Al-Sannaa NA, Faqeih EA, Alfadhel M, Cheema HA, Dupont J, Bézieau S, Isidor B, Low DY, Wang Y, Tan G, Lai PS, Piloquet H, Joubert M, Kayserili H, Kripps KA, Nahas SA, Wartchow EP, Warren M, Bhavani GS, Dasouki M, Sandoval R, Carvalho E, Ramos L, Porta G, Wu B, Lashkari HP, AlSaleem B, BaAbbad RM, Abreu Ferrão AN, Karageorgou V, Ordonez-Herrera N, Khan S, Bauer P, Cogne B, Bertoli-Avella AM, Vincent M, Girisha KM, Reversade B. Moreno Traspas R, et al. Nat Genet. 2022 Aug;54(8):1214-1226. doi: 10.1038/s41588-022-01120-0. Epub 2022 Jul 21. Nat Genet. 2022. PMID: 35864190 Free PMC article.
A four-month gatifloxacin-containing regimen for treating tuberculosis.
Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah B, Kassa F, N'Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis C, Lapujade O, Olliaro PL, Lienhardt C; OFLOTUB/Gatifloxacin for Tuberculosis Project. Merle CS, et al. N Engl J Med. 2014 Oct 23;371(17):1588-98. doi: 10.1056/NEJMoa1315817. N Engl J Med. 2014. PMID: 25337748 Free article. Clinical Trial.
There was heterogeneity across countries (P=0.02 for interaction, with differences in the rate of an unfavorable outcome ranging from -5.4 percentage points in Guinea to 12.3 percentage points in Senegal) and in baseline cavitary status (P=0.04 for interaction) and …
There was heterogeneity across countries (P=0.02 for interaction, with differences in the rate of an unfavorable outcome ranging from …
Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y; Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Iijima K, et al. Lancet. 2014 Oct 4;384(9950):1273-81. doi: 10.1016/S0140-6736(14)60541-9. Epub 2014 Jun 22. Lancet. 2014. PMID: 24965823 Clinical Trial.
The median relapse-free period was significantly longer in the rituximab group (267 days, 95% CI 223-374) than in the placebo group (101 days, 70-155; hazard ratio: 0.27, 0.14-0.53; p<0.0001). Ten patients (42%) in the rituximab group and six (25%) in the placebo group …
The median relapse-free period was significantly longer in the rituximab group (267 days, 95% CI 223-374) than in the placebo group (101 day …
33 results